1,https://www.reuters.com/article/us-medtronic-results/medtronic-expects-covid-19-vaccine-to-aid-return-to-pre-pandemic-growth-levels-idUSKBN2841NS,2020-11-24T18:15:12Z,Medtronic expects COVID-19 vaccine to aid return to pre-pandemic growth levels,"(Reuters) - A vaccine for COVID-19 will help Medtronic Plc reach pre-pandemic growth levels by fiscal fourth quarter, Chief Executive Officer Geoff Martha told Reuters on Tuesday.","“There is some sort of psychological impact on patients and physicians having more confidence knowing that it (vaccine) is coming,” Martha said during a post-earnings interview.",The comments come as the United States prepares to distribute the first round of vaccines against the novel coronavirus by mid-December.,"Shares of the medical device maker rose nearly 4%, after the company also beat profit estimates for the second quarter.","Medtronic said demand for non-urgent procedures continued to improve in the quarter and the first weeks of November, from the lows recorded during the peak of the pandemic, echoing comments from rival Abbott Laboratories.","Many medical device makers have suffered as movement restrictions and overworked hospital systems led to delays in elective surgeries, which affected product sales.","Martha said Medtronic and its peers will get back to more normal growth, as the virus subsides and hospital capacity ramps back up.",Medtronic also said it was cautiously optimistic about seeing a limited impact from a second wave of COVID-19 related hospitalizations and infections.,"“Hospitals are better equipped now to handle COVID-19 patients and remain open to serve non-COVID patients,” Medtronic Chief Financial Officer Karen Parkhill said during a post-earnings conference call.","“And over time and with education, patient fear is not as heightened as it was last spring and early summer.”","Excluding items, Medtronic earned $1.02 per share in the second quarter, beating analysts’ expectation of 80 cents per share, according to Refinitiv IBES data.","It did not provide annual or quarterly financial targets, citing uncertainty from the pandemic."
2,https://www.reuters.com/article/medtronic-results/medtronic-second-quarter-profit-slumps-on-deferred-care-idUSL4N2IA2QP,2020-11-24T11:53:26Z,Medtronic second-quarter profit slumps on deferred care,"Nov 24 (Reuters) - Medtronic Plc reported a 64% fall in quarterly profit on Tuesday, partly hurt by a decline in sales of its medical devices as rising COVID-19 cases delayed elective surgeries.","Net income attributable to the company fell to $489 million, or 36 cents per share, in the second quarter ended Oct. 30, from $1.36 billion, or $1.01 per share, a year earlier. (Reporting by Manojna Maddipatla and Amruta Khandekar in Bengaluru; Editing by Shinjini Ganguli)"
3,https://www.reuters.com/article/us-medtronic-ventilators/medtronic-under-justice-department-probe-over-ventilator-competition-wsj-idUSKBN26L3S1,2020-10-01T15:51:01Z,Medtronic under Justice Department probe over ventilator competition: WSJ,(This September 30 story corrects paragraph 4 to say probe is only on Covidien-Newport deal),"(Reuters) - The U.S. Justice Department is investigating if acquisitions by medical device maker Medtronic Plc MDT.N hindered competition in ventilator manufacturing, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.","Demand for ventilators sky-rocketed following the coronavirus outbreak in the United States, leading President Donald Trump to sign an order for General Motors GM.N to start making ventilators.","Medtronic has received a civil subpoena from the department requesting more information, according to the report. (on.wsj.com/2GkYjMC)","The probe focuses on an acquisition when Covidien Plc bought a small manufacturer of ventilator systems Newport Medical Instruments in 2012, the report said. Covidien was bought by Medtronic in 2015.","“Medtronic is cooperating fully with DOJ’s review of the 2012 Covidien-Newport transaction,” said Medtronic spokesperson Ben Petok, adding that the deal was appropriately assessed and approved by the Federal Trade Commission in 2012.","Petok said rather than discontinue the Newport family of ventilators, Medtronic continues to market them.",Medtronic has ramped up production of ventilators and partnered reut.rs/2GgTuE6 with Foxconn in June to increase production of ventilators critical in the care of COVID-19 patients.,"Petok also highlighted competitiveness in the ventilator market, with at least 10 major players in which the top five account for about 50% market share.",Shares of Medtronic was marginally down at $102.85 in extended trade.
4,https://www.reuters.com/article/medtronic-ventilators/medtronic-under-justice-department-probe-over-ventilator-competition-wsj-idUSL4N2GR4IA,2020-09-30T21:00:31Z,Medtronic under Justice Department probe over ventilator competition - WSJ,"Sept 30 (Reuters) - The U.S. Justice Department is investigating if acquisitions by medical device maker Medtronic Plc hindered competition in ventilator manufacturing, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.","The company has received a civil subpoena from the department requesting more information on the same, according to the report. (on.wsj.com/2GkYjMC)",Medtronic did not immediately respond to a Reuters request for comment. (Reporting by Trisha Roy in Bengaluru; Editing by Sriraj Kalluvila)
5,https://www.reuters.com/article/us-medtronic-restructuring/medtronic-eyes-450-million-475-million-in-annual-cost-savings-through-restructuring-idUSKBN25T01V,2020-09-02T00:40:11Z,Medtronic eyes $450 million-$475 million in annual cost savings through restructuring,"(Reuters) - Medtronic Plc MDT.N on Tuesday said it would cut costs by $450 million to $475 million a year by fiscal 2023 as the medical device maker embarks on a restructuring exercise to create focused ""operating units"" from its existing businesses.",The Dublin-based company said in a regulatory filing here it would move to the new model beginning in its fiscal third quarter and that the operating units would focus on specific therapy areas.,"The world’s largest standalone medical device maker is also assessing the impact of these changes to the reporting of its four business segments: minimally invasive therapies group, restorative therapies group, diabetes group and cardiac and vascular group.","As a result of the restructuring program, the company expects to incur $400 million-$450 million in costs by the end of fiscal 2022."
6,https://www.reuters.com/article/us-medtronic-results/medtronic-profit-beats-as-demand-for-devices-rebounds-from-pandemic-lows-idUSKBN25L19T,2020-08-25T15:14:38Z,Medtronic profit beats as demand for devices rebounds from pandemic lows,"(Reuters) - Medtronic Plc MDT.N beat analysts' estimates for quarterly profit on Tuesday, and forecast improving demand for its medical devices in the back half of the year as patients catch up on procedures deferred during coronavirus-induced lockdowns.","Shares of the Dublin-based company, the last among major medical device makers to report quarterly results, were up 4% at $104.50 as it joined peers in saying that demand for less urgent medical procedures had recovered from the lows experienced in April.","“Our average daily sales rate saw a significant step-up in May and then again in June, and that continued into July and August,” Chief Financial Officer Karen Parkhill said on a post-earnings conference call.","Medtronic, however, did not provide a financial outlook for the year, citing the uncertainty caused by the pandemic.","The company’s expectation of continued sequential growth “seems highly plausible,” Cowen analyst Joshua Jennings said.","The world’s largest standalone medical device maker also posted a more than two-fold jump in sales of ventilators in the first quarter, as it boosted output to meet a surge in demand for the devices used to help severely ill COVID-19 patients breathe.","“We increased our internal ventilator production fivefold in a matter of just a few months from 200 a week to over 1,000 a week,” Chief Executive Officer Geoffrey Martha said.","Sales at Medtronic’s minimally invasive therapies business, which makes surgical instruments to treat hernias and kidney diseases, fell 14.2%.","Excluding items, the company earned 62 cents per share in the first quarter ended July 31, beating the average expectation of 18 cents per share, according to Refinitiv IBES data.","Revenue fell 13.2% to $6.51 billion, but was above estimates of $5.54 billion."
7,https://www.reuters.com/article/usa-stocks/us-stocks-wall-st-muted-as-apple-overshadows-positive-trade-deal-cues-idUSL4N2FR3PN,2020-08-25T14:45:47Z,US STOCKS-Wall St muted as Apple overshadows positive trade deal cues,"(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.)","* Medtronic, J.M. Smucker rise after results","* Best Buy warns of slowing sales growth, shares fall",* U.S. consumer confidence hits six-year low,"* Indexes dip: Dow 0.30%, S&P 0.05%, Nasdaq 0.15% (Updates to open)",Aug 25 (Reuters) - Wall Street’s main indexes slipped on Tuesday following a three-day rally as a drop in Apple shares overshadowed optimism from remarks made by U.S. and China officials in pledging firm commitment to a Phase One trade deal.,The benchmark S&P 500 opened at a record high as the news eased some concerns that the deal could be on shaky ground. Investors also anticipate the centerpiece event of the week - an annual conference of U.S. central bankers where Federal Reserve Chairman Jerome Powell is scheduled to speak.,"“Both countries believe it’s in their interest to cut a deal and are making noise that they don’t want to let political concerns to interfere with the trade and also disrupt the world economy,” said Christopher Grisanti, chief equity strategist at MAI Capital Management in Cleveland, Ohio.","The S&P 500 and the Nasdaq logged new closing highs on Monday, boosted by signs of progress in developing treatments and vaccines for COVID-19. The benchmark index surpassed its pre-pandemic high last week even as recent economic indicators signaled a bumpy recovery from the virus-led downturn.",A survey from the Conference Board showed U.S. consumer confidence unexpectedly fell in August to hit a six-year low.,"Among stocks, Salesforce.com Inc, Amgen Inc and Honeywell International Inc climbed between 2.9% and 5% on news they would join the blue-chip Dow Jones Industrial Average index on Aug. 31.",Cloud computing heavyweight Salesforce.com is also expected to report second-quarter results after markets close.,"The three companies will replace Exxon Mobil Corp, Pfizer Inc and Raytheon Technologies Corp, which were down between 1.4% and 1.9%.","Apple Inc slipped 1.7%, set to snap a five-day winning streak and weighing heavily on the three main indexes.","At 10:08 a.m. ET, the Dow Jones Industrial Average was down 85.39 points, or 0.30%, at 28,223.07, the S&P 500 was down 1.85 points, or 0.05%, at 3,429.43. The Nasdaq Composite was down 17.34 points, or 0.15%, at 11,362.38.","The healthcare sector, which got a lift from Amgen and Medtronic shares, as well as economically-sensitive financials and industrials, outperformed among the major S&P sectors.",Medtronic rose 3.7% after the company said demand for medical devices was improving as elective surgeries picked up pace while it posted a plunge in first-quarter profit.,J.M. Smucker Co jumped 8.3% after the Folgers coffee maker raised its forecast for fiscal 2021 adjusted profit.,Consumer electronics retailer Best Buy Co Inc fell 7% as it warned sales growth may slow in the coming weeks.,Advancing issues matched decliners on the NYSE and outnumbered them by a 1.27-to-1 ratio on the Nasdaq.,"The S&P index recorded 21 new 52-week highs and no new low, while the Nasdaq recorded 38 new highs and 12 new lows. (Reporting by Medha Singh and Devik Jain in Bengaluru; Editing by Arun Koyyur and Bernard Orr)"
8,https://www.reuters.com/article/medtronic-results/medtronic-profit-falls-nearly-44-as-covid-19-hurts-demand-idUSL4N2FR2TS,2020-08-25T10:52:19Z,Medtronic profit falls nearly 44% as COVID-19 hurts demand,Aug 25 - Medtronic Plc reported a 43.6% fall in quarterly profit on Tuesday as a decline in demand for elective surgeries due to the COVID-19 pandemic hit sales of its medical devices.,"Net income attributable to the company fell to $487 million, or 36 cents per share, in the first quarter ended July 31, from $864 million, or 64 cents per share, a year earlier.",Revenue fell to $6.51 billion from $7.49 billion. (Reporting by Dania Nadeem and Manojna Maddipatla in Bengaluru; Editing by Aditya Soni)
9,https://www.reuters.com/article/brief-medtronic-and-tandem-diabetes-care/brief-medtronic-and-tandem-diabetes-care-enter-into-patent-cross-license-agreement-idUSASN00095W,2020-07-09T13:18:29Z,BRIEF-Medtronic And Tandem Diabetes Care Enter Into Patent Cross-License Agreement,July 9 (Reuters) - Tandem Diabetes Care Inc:,* MEDTRONIC AND TANDEM DIABETES CARE ENTER INTO PATENT CROSS-LICENSE AGREEMENT,* TANDEM DIABETES CARE INC - NO PAYMENTS WILL BE EXCHANGED AS PART OF THIS AGREEMENT AND FURTHER TERMS WERE NOT DISCLOSED Source text for Eikon: Further company coverage:
10,https://www.reuters.com/article/brief-medtronic-introduces-minimed-mio-a/brief-medtronic-introduces-minimed-mio-advance-infusion-set-enabling-fewer-insertion-steps-for-people-with-diabetes-in-u-s-idUSFWN2EE0HU,2020-07-07T13:26:35Z,BRIEF-Medtronic Introduces Minimed Mio Advance Infusion Set Enabling Fewer Insertion Steps For People With Diabetes In U.S.,July 7 (Reuters) - Medtronic PLC:,* MEDTRONIC INTRODUCES MINIMED™ MIO™ ADVANCE INFUSION SET ENABLING FEWER INSERTION STEPS FOR PEOPLE WITH DIABETES IN THE U.S. Source text for Eikon: Further company coverage:
11,https://www.reuters.com/article/brief-medtronic-gains-fda-clearance-ce-m/brief-medtronic-gains-fda-clearance-ce-mark-for-linq-ii-insertable-cardiac-monitor-idUSFWN2EE0I6,2020-07-07T13:18:33Z,"BRIEF-Medtronic Gains FDA Clearance, CE Mark For Linq II™ Insertable Cardiac Monitor",July 7 (Reuters) - Medtronic PLC:,"* MEDTRONIC GAINS FDA CLEARANCE, CE MARK FOR LINQ II™ INSERTABLE CARDIAC MONITOR (ICM) Source text for Eikon: Further company coverage:"
12,https://www.reuters.com/article/brief-medtronic-begins-real-world-post-m/brief-medtronic-begins-real-world-post-market-study-of-the-valiant-navion-thoracic-stent-graft-system-idUSFWN2ED0FB,2020-07-06T15:34:52Z,BRIEF-Medtronic Begins Real-World Post-Market Study Of The Valiant Navion Thoracic Stent Graft System,July 6 (Reuters) - Medtronic PLC:,* MEDTRONIC BEGINS REAL-WORLD POST-MARKET STUDY OF THE VALIANT NAVION THORACIC STENT GRAFT SYSTEM IN PATIENTS WITH THORACIC AORTIC DISSECTION Source text for Eikon: Further company coverage:
13,https://www.reuters.com/article/brief-new-real-world-data-from-medtronic/brief-new-real-world-data-from-medtronic-global-symplicity-registry-show-renal-denervation-lowered-blood-pressure-in-patients-with-hypertension-out-to-3-years-idUSFWN2E20QS,2020-06-25T15:49:08Z,BRIEF-New Real-World Data From Medtronic Global SYMPLICITY Registry Show Renal Denervation Lowered Blood Pressure In Patients With Hypertension Out To 3 Years,June 25 (Reuters) - Medtronic PLC:,* NEW REAL-WORLD DATA FROM MEDTRONIC GLOBAL SYMPLICITY REGISTRY SHOW RENAL DENERVATION LOWERED BLOOD PRESSURE IN PATIENTS WITH HYPERTENSION OUT TO THREE YEARS,"* MEDTRONIC - STUDY SHOWED RDN LED TO SIGNIFICANT, CLINICALLY MEANINGFUL REDUCTIONS IN BLOOD PRESSURE THAT WERE SUSTAINED OUT TO 3 YRS POST-PROCEDURE",* MEDTRONIC PLC - RDN CONTINUED TO SHOW A STRONG SAFETY PROFILE AT 3 YRS WITH INCIDENCE OF RENAL ARTERY STENOSIS OF 0.3% Source text for Eikon: Further company coverage:
14,https://www.reuters.com/article/us-health-coronavirus-medtronic/medtronic-ties-up-with-foxconn-to-boost-ventilator-production-idUSKBN23P27H,2020-06-18T13:12:26Z,Medtronic ties up with Foxconn to boost ventilator production,"(Reuters) - Medtronic said on Thursday it had partnered with Foxconn to boost production of its ventilators to 10,000 over the next year amid surging demand as the respiratory disease caused by the new coronavirus overwhelms hospitals.","The ventilators will be marketed and sold by Medtronic and produced by Foxconn, formally known as Hon Hai Precision Industry Co Ltd, at the Taiwanese company’s facilities in Wisconsin. [nGNEzDGbX]","If needed, Medtronic and Foxconn can increase their production capacity to more than double the current Foxconn ventilator commitment, the companies said in a joint statement.","Several companies, including General Motors Co, General Electric and ResMed Inc, have been ramping up ventilator production to stem a potential shortage."
15,https://www.reuters.com/article/health-coronavirus-medtronic/medtronic-partners-with-foxconn-to-boost-ventilator-production-idUSL4N2DV3FQ,2020-06-18T12:44:50Z,Medtronic partners with Foxconn to boost ventilator production,June 18 (Reuters) - Medical device maker Medtronic said on Thursday it had partnered with Foxconn to increase production of its ventilators that are critical in the care of patients with COVID-19. (Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
16,https://www.reuters.com/article/brief-medtronic-and-foxconn-partner-to-i/brief-medtronic-and-foxconn-partner-to-increase-ventilator-production-idUSFWN2DV0IJ,2020-06-18T12:41:53Z,BRIEF-Medtronic And Foxconn Partner To Increase Ventilator Production,June 18 (Reuters) - Medtronic PLC:,* MEDTRONIC AND FOXCONN PARTNER TO INCREASE VENTILATOR PRODUCTION Source text for Eikon: Further company coverage:
17,https://www.reuters.com/article/brief-medtronic-and-foxconn-partner-to-i/brief-medtronic-and-foxconn-partner-to-increase-ventilator-production-idUSFWN2DV0II,2020-06-18T12:41:43Z,BRIEF-Medtronic And Foxconn Partner To Increase Ventilator Production,June 18 (Reuters) - Medtronic PLC:,* MEDTRONIC AND FOXCONN PARTNER TO INCREASE VENTILATOR PRODUCTION,"* MEDTRONIC - CO, FOXCONN ARE CURRENTLY RAMPING UP PLANS TO PRODUCE 10,000 PB560 VENTILATORS OVER NEXT YEAR",* MEDTRONIC - VENTILATORS WILL BE MARKETED AND SOLD BY MEDTRONIC Source text for Eikon: Further company coverage:
18,https://www.reuters.com/article/brief-abre-study-meets-primary-safety-an/brief-abre-study-meets-primary-safety-and-effectiveness-endpoints-idUSFWN2DT0JF,2020-06-16T16:03:31Z,BRIEF-ABRE Study Meets Primary Safety And Effectiveness Endpoints,June 16 (Reuters) - Medtronic PLC:,* ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS,* MEDTRONIC SELF-EXPANDING VENOUS STENT DEMONSTRATES FAVORABLE OUTCOMES IN PATIENTS WITH VENOUS OUTFLOW OBSTRUCTION,* STUDY MET ITS PRIMARY SAFETY ENDPOINT WITH A 2.0% (4/200) RATE OF MAJOR ADVERSE EVENTS WITHIN 30 DAYS,* ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS,* DATA DEMONSTRATED A FREEDOM FROM CLINICALLY DRIVEN TARGET LESION REVASCULARIZATION RATE OF 92.4%,* NO STENT FRACTURES AND NO DELAYED STENT MIGRATION OBSERVED WITHIN 12 MONTHS IN STUDY Source text for Eikon: Further company coverage:
19,https://www.reuters.com/article/brief-medtronic-says-received-ce-mark-fo/brief-medtronic-says-received-ce-mark-for-micra-av-transcatheter-pacing-system-idUSFWN2DS0TI,2020-06-15T13:17:21Z,BRIEF-Medtronic Says Received CE Mark For Micra AV Transcatheter Pacing System,June 15 (Reuters) - Medtronic PLC:,* MEDTRONIC MICRA™ AV RECEIVES CE MARK,* MEDTRONIC PLC - HAS RECEIVED CE MARK FOR MICRA AV TRANSCATHETER PACING SYSTEM Source text for Eikon: Further company coverage:
20,https://www.reuters.com/article/brief-medtronic-announces-a-337-mln-prod/brief-medtronic-announces-a-337-mln-product-investment-from-blackstone-life-sciences-to-expand-development-of-future-diabetes-technologies-idUSFWN2DP0RS,2020-06-12T21:57:15Z,BRIEF-Medtronic Announces A $337 Mln Product Investment From Blackstone Life Sciences To Expand Development Of Future Diabetes Technologies,June 12 (Reuters) - Medtronic PLC:,* MEDTRONIC ANNOUNCES A $337 MILLION PRODUCT INVESTMENT FROM BLACKSTONE LIFE SCIENCES TO EXPAND DEVELOPMENT OF FUTURE DIABETES TECHNOLOGIES,* MEDTRONIC PLC - MEDTRONIC IS NOT DISCLOSING SPECIFIC DEVELOPMENT PROGRAMS,"* MEDTRONIC - IF SUCCESSFULLY COMMERCIALIZED, CO TO PAY ROYALTIES EXPECTED TO BE IN LOW- TO MID-SINGLE DIGIT RANGE AS % OF SALES",* MEDTRONIC PLC - WILL RECEIVE UP TO $337 MILLION IN FUNDING OVER NEXT SEVERAL YEARS TO FUND FOUR IDENTIFIED DIABETES RESEARCH AND DEVELOPMENT PROGRAMS,* MEDTRONIC PLC - ADDITIONAL TERMS OF ARRANGEMENT WERE NOT DISCLOSED. Source text for Eikon: Further company coverage:
21,https://www.reuters.com/article/brief-medtronic-presents-us-pivotal-tria/brief-medtronic-presents-u-s-pivotal-trial-data-for-minimed-780g-advanced-hybrid-closed-loop-system-with-automated-correction-bolus-feature-idUSFWN2DP0IF,2020-06-12T21:49:29Z,BRIEF-Medtronic Presents U.S. Pivotal Trial Data For Minimed 780G Advanced Hybrid Closed Loop System With Automated Correction Bolus Feature,June 12 (Reuters) - Medtronic PLC:,* MEDTRONIC PRESENTS U.S. PIVOTAL TRIAL DATA FOR MINIMED™ 780G ADVANCED HYBRID CLOSED LOOP SYSTEM WITH AUTOMATED CORRECTION BOLUS FEATURE,* MEDTRONIC PLC - DATA FROM CLINICAL TRIALS OF AUTOMATED INSULIN PUMP DEMONSTRATES POSITIVE RESULTS FOR PATIENTS WITH TYPE 1 DIABETES Source text for Eikon: Further company coverage:
22,https://www.reuters.com/article/brief-medtronic-secures-ce-mark-for-mini/brief-medtronic-secures-ce-mark-for-minimed-780g-system-designed-to-simplify-type-1-diabetes-management-idUSFWN2DO0P3,2020-06-11T13:17:37Z,BRIEF-Medtronic Secures CE Mark For MiniMed 780G System Designed to Simplify Type 1 Diabetes Management,June 11 (Reuters) - Medtronic PLC:,* MEDTRONIC SECURES CE MARK FOR MINIMED™ 780G ADVANCED HYBRID CLOSED LOOP SYSTEM DESIGNED TO FURTHER SIMPLIFY TYPE 1 DIABETES MANAGEMENT,* MEDTRONIC PLC - MINIMED 780G SYSTEM IS EXPECTED TO BEGIN SHIPPING THIS FALL IN SELECT COUNTRIES IN EUROPE,"* MEDTRONIC PLC - IN UNITED STATES, MINIMED 780G SYSTEM IS INVESTIGATIONAL USE ONLY AND NOT APPROVED FOR SALE Source text for Eikon: Further company coverage:"
23,https://www.reuters.com/article/brief-medtronic-secures-ce-mark-for-mini/brief-medtronic-secures-ce-mark-for-minimed-780g-advanced-hybrid-closed-loop-system-idUSFWN2DO0P8,2020-06-11T13:09:52Z,BRIEF-Medtronic Secures CE Mark For MiniMed 780G Advanced Hybrid Closed Loop System,June 11 (Reuters) - Medtronic PLC:,* MEDTRONIC - SECURES CE MARK FOR MINIMED 780G ADVANCED HYBRID CLOSED LOOP SYSTEM DESIGNED TO FURTHER SIMPLIFY TYPE 1 DIABETES MANAGEMENT,* MEDTRONIC PLC - MINIMED SYSTEM EXPECTED TO BEGIN SHIPPING THIS FALL IN SELECT COUNTRIES IN EUROPE,"* MEDTRONIC PLC - IN U.S., MINIMED 780G SYSTEM IS INVESTIGATIONAL USE ONLY AND NOT APPROVED FOR SALE Source text for Eikon: Further company coverage:"
24,https://www.reuters.com/article/brief-medtronic-resolute-onyx-des-receiv/brief-medtronic-resolute-onyx-des-receives-first-and-only-one-month-dapt-indication-for-high-bleeding-risk-patients-in-europe-idUSFWN2DI0H9,2020-06-05T15:59:20Z,BRIEF-Medtronic Resolute Onyx Des Receives First And Only One-Month DAPT Indication For High Bleeding Risk Patients In Europe,June 5 (Reuters) - Medtronic PLC:,* MEDTRONIC RESOLUTE ONYX™ DES RECEIVES FIRST AND ONLY ONE-MONTH DAPT INDICATION FOR HIGH BLEEDING RISK PATIENTS IN EUROPE,* MEDTRONIC PLC - RESOLUTE ONYX DES IS NOT CURRENTLY INDICATED FOR HBR PATIENTS WITH ONE-MONTH DAPT IN UNITED STATES Source text for Eikon: Further company coverage:
25,https://www.reuters.com/article/brief-titan-medical-reports-development/brief-titan-medical-reports-development-and-license-agreements-with-medtronic-idUSASA00SPO,2020-06-04T11:35:09Z,BRIEF-Titan Medical Reports Development And License Agreements With Medtronic,June 4 (Reuters) - Titan Medical Inc:,* TITAN MEDICAL ANNOUNCES DEVELOPMENT AND LICENSE AGREEMENTS WITH MEDTRONIC AND SENIOR SECURED LOAN,* TITAN MEDICAL - ENTERED INTO DEVELOPMENT AND LICENSE AGREEMENT WITH MEDTRONIC PLC TO FURTHER DEVELOPMENT OF ROBOTIC ASSISTED SURGICAL TECHNOLOGIES,* TITAN MEDICAL - ENTERED INTO SEPARATE LICENSE AGREEMENT WITH MEDTRONIC IN RESPECT OF CERTAIN INTELLECTUAL PROPERTY OF TITAN,* TITAN MEDICAL - TITAN WILL RECEIVE SERIES OF PAYMENTS TOTALING UP TO U.S. $31 MILLION FOR MEDTRONIC’S LICENSE TO ROBOTIC ASSISTED SURGICAL TECHNOLOGIES,"* TITAN MEDICAL - A MILESTONE OF AGREEMENT IS FOR CO TO RAISE ADDED $18 MILLION WITHIN 4 MONTHS OF DEVELOPMENT START DATE, EXPECTED TO OCCUR IN JUNE",* TITAN MEDICAL - MEDTRONIC HAS LICENSED CERTAIN ROBOTIC ASSISTED SURGICAL TECHNOLOGIES FROM TITAN FOR AN UPFRONT PAYMENT OF U.S. $10 MILLION,* TITAN MEDICAL - TITAN RETAINS RIGHTS TO CONTINUE TO DEVELOP AND COMMERCIALIZE CERTAIN ROBOTIC ASSISTED SURGICAL TECHNOLOGIES FOR ITS OWN BUSINESS,"* TITAN MEDICAL INC - CHARLES FEDERICO, WHO HAS SERVED AS CO’S CHAIRMAN SINCE MAY 2019 DECIDED TO RETIRE FROM TITAN’S BOARD","* TITAN MEDICAL INC - DAVID MCNALLY, TITAN’S PRESIDENT AND CEO, HAS BEEN APPOINTED CHAIRMAN OF BOARD OF DIRECTORS Source text for Eikon: Further company coverage:"
26,https://www.reuters.com/article/brief-medtronic-plc-announced-us-fda-app/brief-medtronic-plc-announced-u-s-fda-approval-for-android-version-of-its-guardian-connect-continuous-glucose-monitoring-system-idUSFWN2D40CB,2020-05-22T13:10:04Z,BRIEF-Medtronic PLC Announced U.S. FDA Approval For Android Version Of Its Guardian Connect Continuous Glucose Monitoring System,May 22 (Reuters) - Medtronic PLC:,* MEDTRONIC PLC - ANNOUNCED U.S. FDA APPROVAL FOR ANDROID™ VERSION OF ITS GUARDIAN™ CONNECT CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM Source text for Eikon: Further company coverage:
27,https://www.reuters.com/article/brief-medtronic-exec-says-less-deferrabl/brief-medtronic-exec-says-less-deferrable-therapies-and-products-like-neurovascular-tavr-cardiac-rhtym-are-coming-back-conf-call-idUSFWN2D309H,2020-05-21T16:01:01Z,"BRIEF-Medtronic Exec Says Less Deferrable Therapies And Products Like Neurovascular, Tavr, Cardiac Rhtym Are Coming Back Conf. Call",May 21 (Reuters) - Medtronic PLC:,* EXEC SAYS IT’S A GOOD TIME TO DO M&A: CONF. CALL,* EXEC SAYS SEEING PROCEDURAL IMPROVEMENTS IN THE U.S. : CONF. CALL,"* EXEC SAYS LESS DEFERRABLE THERAPIES AND PRODUCTS LIKE NEUROVASCULAR, TAVR, CARDIAC RHTYM ARE COMING BACK : CONF. CALL",* EXEC SAYS PACEMAKERS ARE COMING BACK VERY QUICKLY : CONF. CALL Further company coverage:
28,https://www.reuters.com/article/brief-medtronic-plc-says-seeing-earlier/brief-medtronic-plc-says-seeing-earlier-than-expected-signs-of-recovery-in-parts-of-the-world-for-medical-procedures-conf-call-idUSFWN2D30PB,2020-05-21T16:00:01Z,BRIEF-Medtronic PLC Says Seeing Earlier-Than-Expected Signs Of Recovery In Parts Of The World For Medical Procedures Conf. Call,May 21 (Reuters) - Medtronic PLC:,* MEDTRONIC PLC SAYS SEEING EARLIER-THAN-EXPECTED SIGNS OF RECOVERY IN PARTS OF THE WORLD FOR MEDICAL PROCEDURES: CONF. CALL Further company coverage:
29,https://www.reuters.com/article/us-medtronic-results/medtronic-warns-of-sales-hit-as-people-delay-non-emergency-surgeries-idUSKBN22X190,2020-05-21T14:55:45Z,Medtronic warns of sales hit as people delay non-emergency surgeries,"(Reuters) - Medical device maker Medtronic Plc MDT.N warned of a significant hit to current-quarter sales on Thursday as Americans are forced to delay less urgent surgeries because of the COVID-19 pandemic, sending its shares down 2%.","Medical device makers have borne the brunt of the coronavirus outbreak as federal and state guidelines ask for elective surgeries such as hip and knee replacements and certain heart procedures to be delayed, sapping the demand for devices used in the surgeries.","The company expects a slow recovery in its restorative therapies unit, which houses neuro-stimulation implants to treat chronic pain, and heart device unit, which sells valves.","“We currently expect first quarter revenue growth to be modestly worse than the fourth quarter,” said Chief Financial Officer Karen Parkhill.","However, the world’s largest standalone medical device maker added that it was seeing early signs of a recovery in some parts of the world and expects a return to more normal revenue growth by the end of fiscal year 2021.","Medtronic said sales of products that are more urgently needed by patients, such as pacemakers used to control abnormal heart rhythms, have started to recover.","Revenue across the company’s segments fell in the fourth quarter, with its heart devices unit taking the biggest hit as customers lowered bulk purchases.","Sales in the unit fell 34.3% to $2 billion in the quarter, while net sales declined 26.4% to $6 billion, missing estimates of $6.17 billion.","Medtronic did not give a forecast for full-year 2021, citing uncertainties surrounding the coronavirus outbreak, but said the company had ample liquidity and increased its quarterly dividend by 7.4% to 58 cents per share.","Excluding items, Medtronic earned 58 cents per share, missing analysts’ expectations of 68 cents."
30,https://www.reuters.com/article/brief-medtronic-reports-q4-revenue-of-6/brief-medtronic-reports-q4-revenue-of-6-bln-hikes-qtrly-dividend-to-0-58-idUSASA00R58,2020-05-21T11:11:12Z,"BRIEF-Medtronic Reports Q4 Revenue Of $6 Bln, Hikes Qtrly Dividend To $0.58",May 21 (Reuters) - Medtronic PLC:,* MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL RESULTS; ANNOUNCES DIVIDEND INCREASE,* Q4 EARNINGS PER SHARE ESTIMATE $0.68 -- REFINITIV IBES DATA,* FINANCIAL RESULTS IN-LINE WITH UPDATE PROVIDED ON APRIL 21,* SPINE Q4 REVENUE OF $480 MILLION DECREASED 31 PERCENT AS REPORTED AND 32 PERCENT ON AN ORGANIC BASIS,* NOT PROVIDING FORMAL ANNUAL OR QUARTERLY FINANCIAL GUIDANCE AT THIS TIME,* CARDIAC AND VASCULAR GROUP Q4 REVENUE OF $2.004 BILLION DECREASED 34 PERCENT AS REPORTED AND 33 PERCENT CONSTANT CURRENCY,* MEDTRONIC - REMAINS COMMITTED TO RETURNING MINIMUM OF 50% OF FREE CASH FLOW TO SHAREHOLDERS,* RTG Q4 REVENUE OF $1.490 BILLION DECREASED 33 PERCENT AS REPORTED AND ON AN ORGANIC BASIS,* MINIMALLY INVASIVE THERAPIES GROUP Q4 REVENUE OF $1.934 BILLION DECREASED 14 PERCENT AS REPORTED AND 12 PERCENT CONSTANT CURRENCY,* COMPANY HAS NO PUBLIC DEBT MATURING UNTIL MARCH 2021 Source text for Eikon: Further company coverage:
31,https://www.reuters.com/article/medtronic-results/medtronic-fourth-quarter-profit-plunges-nearly-45-on-covid-19-hit-idUSL4N2D32N8,2020-05-21T10:53:19Z,Medtronic fourth-quarter profit plunges nearly 45% on COVID-19 hit,May 21 (Reuters) - Medical device maker Medtronic PLC reported a 44.9% fall in fourth-quarter profit on Thursday as it took a hit from delays in elective surgeries due to the COVID-19 pandemic.,"Net income attributable to the company fell to $646 million, or 48 cents per share, in the quarter ended April 24, from $1.17 billion, or 87 cents per share, a year earlier.",The company however said it had ample liquidity and raised its quarterly dividend.
32,https://www.reuters.com/article/brief-jeffrey-j-popma-to-join-medtronic/brief-jeffrey-j-popma-to-join-medtronic-as-vice-president-and-chief-medical-officer-for-coronary-renal-denervation-and-structural-heart-businesses-idUSASA00QPO,2020-05-18T22:45:44Z,"BRIEF-Jeffrey J. Popma To Join Medtronic As Vice President And Chief Medical Officer For Coronary, Renal Denervation, And Structural Heart Businesses",May 18 (Reuters) - Medtronic PLC:,"* JEFFREY J. POPMA, M.D. TO JOIN MEDTRONIC AS VICE PRESIDENT AND CHIEF MEDICAL OFFICER FOR CORONARY, RENAL DENERVATION, AND STRUCTURAL HEART BUSINESSES Source text for Eikon: Further company coverage:"
33,https://www.reuters.com/article/brief-medtronic-says-unit-entered-into-t/brief-medtronic-says-unit-entered-into-term-loan-agreement-idUSFWN2CV0RG,2020-05-13T21:30:40Z,BRIEF-Medtronic Says Unit Entered Into Term Loan Agreement,May 13 (Reuters) - Medtronic PLC:,* MEDTRONIC PLC - ON MAY 12 UNIT ENTERED INTO A TERM LOAN AGREEMENT,* MEDTRONIC PLC - LOAN AGREEMENT PROVIDES FOR AN UNSECURED TERM LOAN OF UP TO JPY 300 BILLION Source text: (bit.ly/3fL79Ad) Further company coverage:
34,https://www.reuters.com/article/brief-medtronic-has-got-fda-approval-for/brief-medtronic-has-got-fda-approval-for-cobalt-crome-implantable-cardioverter-defibrillators-cardiac-resynchronization-therapy-defibrillators-idUSFWN2CI1IR,2020-05-08T12:22:40Z,BRIEF-Medtronic - Has Got FDA Approval For Cobalt & Crome Implantable Cardioverter-Defibrillators & Cardiac Resynchronization Therapy-Defibrillators,May 8 (Reuters) - Medtronic PLC:,* MEDTRONIC - HAS GOT FDA APPROVAL FOR COBALT & CROME IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS & CARDIAC RESYNCHRONIZATION THERAPY-DEFIBRILLATORS Source text for Eikon: Further company coverage:
35,https://www.reuters.com/article/us-heatlth-coronavirus-medtronic/medtronic-sees-hit-to-revenue-as-hospitals-delay-elective-procedures-idUSKCN22402M,2020-04-22T00:34:23Z,Medtronic sees hit to revenue as hospitals delay elective procedures,"(Reuters) - Medtronic Plc MDT.N said on Tuesday its revenues across the world had plunged in recent weeks, as hospitals put off elective procedures that use its medical devices in order to save capacity to treat COVID-19 patients.","Weekly revenue from the United States declined about 60%, excluding bulk purchases, over the last few weeks, as hospitals focused their efforts on treating surging numbers of patients infected with the novel coronavirus, the world’s largest standalone medical device maker said.","Weekly revenue from China, where the pandemic started, has declined 20% to 40% since March 9, adding to the dent it expects to its overall fourth-quarter sales.","More than 2.5 million people globally have been reported to be infected by the virus and over 170,000 have died.","The company said it was running many of its factories at or near full capacity to have adequate stocks to support an anticipated rebound in procedures and was still on pace to ramp up production of much-needed ventilators by nearly five-fold to more than 1,000 per week by June-end.","Medtronic said it was in a strong position in terms of liquidity, with about $11 billion in cash and investments as of the most recent quarter, and an undrawn $3.5 billion credit facility."
36,https://www.reuters.com/article/brief-medtronic-plc-targeting-manufactur/brief-medtronic-plc-targeting-manufacturing-of-more-than-1000-ventilators-per-week-by-end-of-june-idUSFWN2BW1IA,2020-04-08T22:33:53Z,"BRIEF-Medtronic PLC - Targeting Manufacturing Of More Than 1,000 Ventilators Per Week By End Of June",Medtronic PLC:,* MEDTRONIC PLC - FDA AUTHORIZES USE OF PB560 IN UNITED STATES,* MEDTRONIC PLC - COMPANY LAUNCHES PB980 REMOTE CAPABILITIES,* MEDTRONIC PLC - MEDTRONIC EXPECTS FIVE-FOLD INCREASE IN ITS VENTILATOR PRODUCTION BY END OF JUNE,* MEDTRONIC PLC - PURITAN BENNETT 560 (PB560) VENTILATOR WILL SOON BE AVAILABLE IN UNITED STATES,* MEDTRONIC PLC - COMPANY EXPECTS PB560 WILL BE AVAILABLE IN U.S. IN MAY.,"* MEDTRONIC PLC - PB560 VENTILATOR AVERAGE SELLING PRICE IS UNDER $10,000 USD.",* MEDTRONIC PLC - CURRENTLY IN LIMITED MARKET RELEASE OF A NEW REMOTE MANAGEMENT CAPABILITY FOR ITS PURITAN BENNETT 980 VENTILATOR WITH TWO HOSPITALS,* MEDTRONIC PLC - MEDTRONIC SHIPS MORE THAN 300 VENTILATORS PER WEEK TO CUSTOMERS,* MEDTRONIC PLC - MEDTRONIC IS PRIORITIZING PB980 AND PB560 PRODUCTION,"* MEDTRONIC PLC - BY END OF APRIL, MEDTRONIC EXPECTS TO MANUFACTURE MORE THAN 400 VENTILATORS PER WEEK.","* MEDTRONIC PLC - BY END OF MAY, COMPANY IS EXPECTING TO MANUFACTURE MORE THAN 700 VENTILATORS PER WEEK","* MEDTRONIC PLC - TARGETING MANUFACTURING OF MORE THAN 1,000 VENTILATORS PER WEEK BY END OF JUNE Source text for Eikon: Further company coverage:"
37,https://www.reuters.com/article/us-health-coronavirus-medtronic/medtronic-wins-u-s-approval-for-ventilator-plans-launch-in-may-idUSKCN21Q389,2020-04-08T21:34:39Z,"Medtronic wins U.S. approval for ventilator, plans launch in May","(Reuters) - Medical device maker Medtronic Plc said on Wednesday it has won the U.S. Food and Drug Administration’s approval to immediately market its ventilator, which it plans to launch by May, to meet increased demand due to the coronavirus outbreak.","The ventilator, PB560, is currently sold in 35 countries at an average selling price of under $10,000, the company said.","As U.S. demand for ventilators skyrockets due to the fast-spreading pandemic, the government is pushing makers to boost their production capacities and has mandated carmakers to use their facilities to produce the device.","The U.S. Health and Human Services Department on Wednesday awarded here two contracts worth more than $1 billion to General Motors Co and Philips, and plans to announce five additional contracts later this week.","Medtronic said it expects to ramp up production by nearly five-fold to more than 1,000 ventilators per week by June-end, and make over 25,000 devices available over the next six months. (reut.rs/2UTAYpZ)","It said it was currently testing a new feature for its PB980 ventilator with two U.S. hospitals that would allow clinicians to adjust settings remotely, reducing physicians’ exposure to patients suffering from COVID-19, the disease caused by the coronavirus."
38,https://www.reuters.com/article/health-coronavirus-medtronic/medtronic-wins-u-s-approval-for-ventilator-plans-launch-in-may-idUSL3N2BW0LI,2020-04-08T20:52:06Z,"Medtronic wins U.S. approval for ventilator, plans launch in May","April 8 (Reuters) - Medical device maker Medtronic Plc said on Wednesday it has won the U.S. Food and Drug Administration’s approval to immediately market its ventilator, which it plans to launch by May, to meet increased demand due to the coronavirus outbreak.","The ventilator, PB560, is currently sold in 35 countries at an average selling price of under $10,000, the company said.","It expects to ramp up production by nearly five-fold to more than 1,000 ventilators per week by June-end, and make over 25,000 devices available over the next six months. (reut.rs/2UTAYpZ)"
39,https://www.reuters.com/article/us-health-coronavirus-foxconn-medtronic/taiwans-foxconn-says-to-make-ventilators-with-medtronic-idUSKBN21Q0DG,2020-04-08T04:02:17Z,Taiwan's Foxconn says to make ventilators with Medtronic,"TAIPEI (Reuters) - Taiwanese electronics manufacturer Foxconn will make ventilators with U.S. firm Medtronic Plc to help patients afflicted by the coronavirus outbreak, the company said on Wednesday.","Foxconn, formally known as Hon Hai Precision Industry Co Ltd, is best known for assembling Apple’s iPhones at factories in China.","In a statement released through company founder Terry Gou’s office, Foxconn said it was currently cooperating with Medtronic to design and develop ventilators, and medical and technical personnel from both firms were working closely on this.","The companies hope to speed up production time so the ventilators can be put to work as soon as possible, it added.",Medtronic Chief Executive Officer Omar Ishrak told CNBC that Foxconn’s Wisconsin plant would be used to make the ventilators.,Other companies in the United States are also rushing to make ventilators as the coronavirus spreads rapidly there.,"Ford Motor Co said last week it will produce 50,000 ventilators over the next 100 days at a plant in Michigan in cooperation with General Electric’s healthcare unit, and can then build 30,000 per month as needed to treat patients infected by the coronavirus."
40,https://www.reuters.com/article/brief-tesla-ceo-musk-says-we-start-deliv/brief-tesla-ceo-musk-says-we-start-delivery-of-intratracheal-medtronic-units-in-nyc-tonight-tweet-idUSFWN2BQ12R,2020-04-02T20:04:20Z,"BRIEF-Tesla CEO Musk Says ""We Start Delivery Of Intratracheal Medtronic Units In NYC Tonight""- Tweet",April 2 (Reuters) -,"* TESLA CEO ELON MUSK SAYS ""WE START DELIVERY OF INTRATRACHEAL MEDTRONIC UNITS IN NYC TONIGHT"" - TWEET Source text : bit.ly/2yp6H9D Further company coverage:"
41,https://www.reuters.com/article/brief-fda-says-medtronic-recalls-pipelin/brief-fda-says-medtronic-recalls-pipeline-flex-embolization-devices-due-to-risk-of-device-fracture-idUSFWN2BN1SI,2020-03-30T17:27:23Z,BRIEF-FDA Says Medtronic Recalls Pipeline Flex Embolization Devices Due To Risk Of Device Fracture,March 30 (Reuters) - U.S. FDA:,* FDA- MEDTRONIC RECALLS PIPELINE FLEX EMBOLIZATION DEVICES DUE TO RISK OF DEVICE FRACTURE,* FDA- IDENTIFIED MEDTRONIC’S RECALL OF PIPELINE FLEX EMBOLIZATION DEVICES AS CLASS I RECALL,* FDA- MEDTRONIC RECALLED 822 PIPELINE FLEX EMBOLIZATION DEVICES IN THE U.S.,"* FDA- GOT 50 MEDICAL DEVICE REPORTS, WITH 10 INJURIES, 1 DEATH, FROM NOV 1, TO MAR 1, RELATED TO MEDTRONIC'S RECALLED PIPELINE FLEX EMBOLIZATION DEVICES Source text: (bit.ly/33UQk0c) Further company coverage:"
42,https://www.reuters.com/article/brief-medtronic-says-evolut-tavr-system/brief-medtronic-says-evolut-tavr-system-demonstrates-excellent-outcomes-in-study-of-low-risk-patients-with-bicuspid-aortic-stenosis-idUSFWN2BL00O,2020-03-29T17:29:58Z,"BRIEF-Medtronic Says Evolut TAVR System Demonstrates ""Excellent"" Outcomes In Study Of Low-Risk Patients With Bicuspid Aortic Stenosis",March 29 (Reuters) - Medtronic PLC:,* MEDTRONIC EVOLUT TAVR SYSTEM DEMONSTRATES EXCELLENT OUTCOMES IN STUDY OF LOW-RISK PATIENTS WITH BICUSPID AORTIC STENOSIS,"* MEDTRONIC PLC SAYS RESULTS FROM 150-PATIENT, SINGLE-ARM STUDY SHOWED EXCELLENT OUTCOMES AT 30 DAYS, WITH A 95.3% DEVICE SUCCESS RATE Source text for Eikon: Further company coverage:"
43,https://www.reuters.com/article/us-health-coronavirus-tesla/tesla-to-reopen-new-york-plant-as-soon-as-humanly-possible-to-make-ventilators-musk-idUSKBN21C3IT,2020-03-25T22:09:24Z,Tesla to reopen New York plant 'as soon as humanly possible' to make ventilators: Musk,"(Reuters) - Tesla Inc TSLA.O will reopen its New York factory ""as soon as humanly possible"" to manufacture ventilators for coronavirus patients, Chief Executive Officer Elon Musk said on Twitter on Wednesday.","Medtronic Plc MDT.N Chief Executive Officer Omar Ishrak told CNBC earlier in the day that the medical device maker has started working with Tesla, which is fast on track to start production of ventilators at Fremont.",Governments across the globe have appealed to automakers and aerospace companies to help procure or make ventilators and other medical equipment.,"Tesla had bought hospital ventilators in China and shipped them to the United States, Musk had said on Tuesday."
44,https://www.reuters.com/article/brief-medtronic-increasing-ventilator-pr/brief-medtronic-increasing-ventilator-production-to-address-covid-19-pandemic-idUSFWN2BB1OM,2020-03-19T00:50:44Z,BRIEF-Medtronic Increasing Ventilator Production To Address Covid-19 Pandemic,March 18 (Reuters) - Medtronic PLC:,* MEDTRONIC INCREASING VENTILATOR PRODUCTION TO ADDRESS COVID-19 PANDEMIC,* WILL MORE THAN DOUBLE ITS CAPACITY TO MANUFACTURE AND SUPPLY VENTILATORS IN RESPONSE TO URGENT NEEDS DUE TO CORONAVIRUS Source text for Eikon: Further company coverage:
45,https://www.reuters.com/article/brief-axonics-announces-filing-of-petiti/brief-axonics-announces-filing-of-petitions-before-the-u-s-patent-and-trademark-office-idUSFWN2B90I7,2020-03-16T10:17:25Z,BRIEF-Axonics Announces Filing Of Petitions Before The U.S. Patent And Trademark Office,March 16 (Reuters) - Axonics Modulation Technologies Inc :,* AXONICS® ANNOUNCES FILING OF PETITIONS BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE CONTESTING THE VALIDITY OF MEDTRONIC PATENTS,* AXONICS- FILING SEVEN PETITIONS BEFORE USPTO REQUESTING INTER PARTES REVIEW TO CONTEST VALIDITY OF PATENTS MEDTRONIC HAS ALLEGED TO BE INFRINGED BY CO Source text for Eikon: Further company coverage:
46,https://www.reuters.com/article/brief-medtronic-limits-all-internal-busi/brief-medtronic-limits-all-internal-business-meetings-that-require-air-travel-unless-they-are-critical-spokesperson-idUSFWN2AY16Y,2020-03-05T22:44:02Z,BRIEF-Medtronic Limits All Internal Business Meetings That Require Air Travel Unless They Are Critical - Spokesperson,March 5 (Reuters) - Medtronic PLC:,* MEDTRONIC HAS LIMITED ALL INTERNAL (EMPLOYEE ONLY) BUSINESS MEETINGS THAT REQUIRE AIR TRAVEL UNLESS THEY ARE BUSINESS CRITICAL - SPOKESPERSON,"* MEDTRONIC SPOKESPERSON SAYS ALSO SUSPENDED TRAVEL INTO AND OUT OF CHINA, OUR ASIA PACIFIC REGION, IRAN, AND NORTHERN ITALY","* MEDTRONIC SPOKESPERSON SAYS AS OF MARCH 4, CO ISSUED UPDATED GUIDANCE RELATED TO BUSINESS TRAVEL, AS WELL AS INTERNAL AND EXTERNAL MEETINGS Further company coverage:"
47,https://www.reuters.com/article/us-medtronic-results/medtronic-misses-revenue-estimates-warns-of-coronavirus-impact-idUSKBN20C1R8,2020-02-18T16:38:17Z,"Medtronic misses revenue estimates, warns of coronavirus impact","(Reuters) - Medtronic Plc MDT.N on Tuesday reported a rare miss in quarterly revenue as demand for its heart devices fell ahead of new launches, and said it would take a hit from the coronavirus outbreak due to delays in hospital procedures in China.",Shares of the world’s largest standalone medical device maker fell 4% to $112.53 in early trading.,Medtronic is the latest company to announce a potential impact to its financial results from the outbreak which has disrupted supply chains and delayed reopening of factories in China.,"Although its manufacturing operations in the country were up and running, Medtronic expects a negative impact from a slowdown in medical device procedures in the region.","“Given the fluidity of this situation, the duration and magnitude of the impact are difficult to quantify at this time,” Chief Executive Officer Omar Ishrak said on a conference call.",Medtronic said it will monitor and assess the impact to its business from coronavirus and provide an update later in the quarter.,"China is a key growth area for the company, housing multiple manufacturing and research facilities with about 7,000 employees, and is expected to contribute to nearly 7% of Medtronic’s revenue this year.",Third-quarter sales at the company’s largest units fell short of estimates from loss of medical procedures due to an upgradation of its supply chain system and as customers held off on buying products ahead of new launches.,"Sales at Medtronic’s top-earning heart devices unit rose 1.2% to $2.82 billion, coming in below the average estimate of $2.86 billion, according to five brokerages polled by Refinitiv.","“Even though much of it was transient...we did not perform at the level we were expecting... We just can’t have surprises like this, for us, nor for you. And we are making changes,” said Geoffrey Martha, who will succeed long-time CEO Ishrak in April.","SVB Leerink analyst Danielle Antalffy questioned whether the issues the company faced during the quarter were indeed “transient”, given Medtronic continues to suffer share losses in areas such as the lucrative transcatheter heart valves market.","The company’s string of small acquisitions to bolster its restorative therapies business helped the unit grow 4.2% to $2.11 billion revenue, but it missed consensus estimate of $2.12 billion, on slowing demand for its pain therapies.","Excluding items, Medtronic earned $1.44 per share, beating consensus estimate of $1.38 per share. Net sales rose 2% to $7.72 billion, missing estimates of $7.81 billion."
48,https://www.reuters.com/article/brief-medtronic-reports-q3-non-gaap-earn/brief-medtronic-reports-q3-non-gaap-earnings-per-share-1-44-idUSASA00DPY,2020-02-18T11:59:19Z,BRIEF-Medtronic Reports Q3 Non-GAAP Earnings Per Share $1.44,Feb 18 (Reuters) - Medtronic PLC:,* Q3 EARNINGS PER SHARE ESTIMATE $1.38 -- REFINITIV IBES DATA,* SEES Q4 NON-GAAP EARNINGS PER SHARE $1.62 TO $1.64 INCLUDING ITEMS,"* “ORGANIC REVENUE GROWTH WAS LIGHT THIS QUARTER, DUE LARGELY TO TRANSIENT ISSUES",* INCREASED ITS FISCAL YEAR 2020 DILUTED NON-GAAP EPS GUIDANCE TO NEW RANGE OF $5.63 TO $5.65,"* MEDTRONIC - COMFORTABLE WITH CURRENT STREET CONSENSUS CALLING FOR Q4 ORGANIC REVENUE GROWTH OF ABOUT 4.5% AND EPS OF $1.64, EXCLUDING ANY IMPACT FROM COVID-19",* COVID-19 IS EXPECTED TO NEGATIVELY AFFECT COMPANY’S Q4 FINANCIAL RESULTS,* DURATION AND MAGNITUDE OF IMPACT OF COVID-19 ARE DIFFICULT TO QUANTIFY AT THIS TIME,* MITG Q3 REVENUE OF $2.176 BILLION INCREASED 2.4% AS REPORTED AND 3.2% CONSTANT CURRENCY,"* IF CURRENT EXCHANGE RATES HOLD, Q4 REVENUE GROWTH WOULD BE NEGATIVELY AFFECTED BY 0.8% TO 1.4%",* RTG Q3 REVENUE OF $2.111 BILLION INCREASED 4.2% AS REPORTED AND 3.6% ON AN ORGANIC BASIS,* CVG Q3 REVENUE OF $2.819 BILLION INCREASED 1.2% AS REPORTED AND 1.8% CONSTANT CURRENCY,* QTRLY BRAIN THERAPIES REVENUE OF $795 MILLION INCREASED 8.6% AS REPORTED,"* SEES Q4 DILUTED NON-GAAP EPS OF $1.62-$1.64, INCLUDING ESTIMATED 3 CENT NEGATIVE IMPACT FROM FOREIGN EXCHANGE BASED ON CURRENT RATES",* QTRLY SPINE REVENUE OF $674 MILLION INCREASED 2.9% AS REPORTED AND DECLINED 0.2% ON AN ORGANIC BASIS,* FY2020 EARNINGS PER SHARE VIEW $5.60 -- REFINITIV IBES DATA,* Q3 REVENUE VIEW $7.81 BILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
49,https://www.reuters.com/article/medtronic-results/medtronic-quarterly-profit-up-51-sees-coronavirus-impact-idUSL4N2AI2XV,2020-02-18T11:56:19Z,"Medtronic quarterly profit up 51%, sees coronavirus impact","Feb 18 (Reuters) - Medtronic Plc on Tuesday reported a 51% rise in third-quarter profit on an income tax gain and higher sales at its top-selling heart devices unit, and said it expects its fourth quarter to take a hit from the coronavirus outbreak.","Net income attributable to the medical device maker rose to $1.92 billion, or $1.42 per share, in the quarter ended Jan. 24, from $1.27 billion, or 94 cents per share, a year earlier.",Net sales rose to $7.72 billion from $7.55 billion.,The company did not quantify the impact from coronavirus. (Reporting By Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
50,https://www.reuters.com/article/us-israel-biotech-grants/israel-grants-33-million-to-ge-medtronic-change-healthcare-to-boost-rd-idUSKBN1K81G4,2018-07-18T11:44:13Z,"Israel grants $33 million to GE, Medtronic, Change Healthcare to boost R&D",JERUSALEM (Reuters) - Three multinational companies have received an Israeli government grant of 120 million shekels ($33 million) aimed at boosting the presence of large companies and establishing Israel as a hub in biotechnology and medicine.,"The grants are part of a new program to boost the field of digital health, inject new intellectual property in Israel, which is expected to generate significant future tax income, and establish a long-term presence for multinational firms.","The companies chosen to participate in the program are medical device firm Medtronic, GE Healthcare, a unit of General Electric, and Change Healthcare, a supplier of digital health solutions.","The companies, which will receive their grants over six years, were selected to expand their research and development centers in Israel, the Israel Innovation Authority said.","“Expanding these R&D centers will help position Israel as a leading player in the field of biomedicine, while creating high quality jobs in the fields of engineering and manufacturing, generating additional exports worth billions of dollars,” Economy Minister Eli Cohen said.",($1 = 3.6426 shekels)
51,https://www.reuters.com/article/us-medtronic-pentagon/medtronic-wins-472-million-u-s-defense-contract-pentagon-idUSKBN1JN36W,2018-06-27T21:45:27Z,Medtronic wins $472 million U.S. defense contract: Pentagon,"WASHINGTON (Reuters) - Medtronic PLC MDT.N has been awarded a $472 million U.S. defense contract for cardiovascular products, the Pentagon said on Wednesday."
52,https://www.reuters.com/article/us-medtronic-results/medtronic-beats-estimates-on-cardio-diabetes-gains-idUSKCN1IP1MF,2018-05-24T15:17:09Z,"Medtronic beats estimates on cardio, diabetes gains","(Reuters) - Medtronic Plc MDT.N topped analysts' estimates for profit in the fourth quarter as it kept a tight lid on costs and upped sales of its heart valves and insulin pumps, offsetting the impact of hurricane damage to production in Puerto Rico.","Shares of the company rose 3 percent as the company outlined 10 percent and 26 percent rises in sales, respectively, in its units which produce cardiac and vascular devices and equipment for diabetics.","That quelled concerns among analysts that events in Puerto Rico and a network service outage which affected the medical device maker’s distribution, ordering and manufacturing would again weigh on results.","“Relative to nervousness that investors have come to expect around Medtronic’s earnings releases, we thought the fourth-quarter print was solid,” Evercore ISI analyst Vijay Kumar said.",The company launched a restructuring plan in January that it hopes will save $500 million to $700 million annually over the next five years and Reuters calculations showed total costs fell to $6.21 billion from $6.29 billion.,"Sales across Medtronic’s business units beat analysts’ estimates, according to Thomson Reuters I/B/E/S, and the company forecast an adjusted profit of $5.10 to $5.15 per share for fiscal 2019 compared to expectations of $5.14.","“We view this as conservative based upon recent new products and others in the new product pipeline, and ongoing cost-control initiatives,” Edward Jones analyst John Boylan said.",Rival Edwards lifesciences EW.N said last month that growth in procedures using its transcatheter heart valves in Europe had been hampered by a shift in market share to Medtronic.,"Sales at Medtronic’s coronary & structural heart sub-unit, which houses the transcatheter valves, rose 18.7 percent to $1.01 billion.","Sales in the broader cardiac and vascular business jumped 10.1 percent to $3.14 billion, beating an average estimate of $3.1 billion while those in the diabetes unit rose 26 percent to $645 million, helped by demand for its new sensor-augmented insulin pumps.","“We know that there’s much work to be done, but we’re as excited and optimistic as our direction is,” Chief Executive Officer Omar Ishrak said on a call with analysts.","Net income attributable to the company jumped 25.5 percent to $1.46 billion, or $1.07 per share, in the quarter ended April 27. Excluding items, the company earned $1.42 per share, beating the average analyst estimate of $1.39."
53,https://www.reuters.com/article/medtronic-results/rpt-medical-device-maker-medtronic-reports-25-5-pct-rise-in-profit-idUSL3N1SV4HG,2018-05-24T11:02:46Z,RPT-Medical device maker Medtronic reports 25.5 pct rise in profit,(Repeats to fix source link with no change to text),May 24 (Reuters) - Medtronic Plc reported a 25.5 percent rise in quarterly profit on Thursday on higher demand for its heart devices.,"Net income attributable to the company rose to $1.46 billion, or $1.07 per share, in the fourth quarter ended April 27, from $1.16 billion, or 84 cents per share, a year earlier.",Revenue rose 2.9 percent to $8.14 billion. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)
54,https://www.reuters.com/article/medtronic-results/medical-device-maker-medtronic-reports-25-5-pct-rise-in-profit-idUSL3N1SV4GF,2018-05-24T10:52:27Z,Medical device maker Medtronic reports 25.5 pct rise in profit,May 24 (Reuters) - Medtronic Plc reported a 25.5 percent rise in quarterly profit on Thursday on higher demand for its heart devices.,"Net income attributable to the company rose to $1.46 billion, or $1.07 per share, in the fourth quarter ended April 27, from $1.16 billion, or 84 cents per share, a year earlier.",Revenue rose 2.9 percent to $8.14 billion. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)
55,https://www.reuters.com/article/brief-new-medtronic-data-shows-blood-pre/brief-new-medtronic-data-shows-blood-pressure-lowering-effect-of-renal-denervation-idUSFWN1SU02J,2018-05-23T08:03:31Z,BRIEF-New Medtronic data shows blood pressure lowering effect of renal denervation,May 23 (Reuters) - Medtronic PLC:,* NEW MEDTRONIC DATA SHOW SIGNIFICANT BLOOD PRESSURE LOWERING EFFECT OF RENAL DENERVATION IN PATIENTS TAKING ANTI-HYPERTENSIVE MEDICATION Source text for Eikon: Further company coverage:
56,https://www.reuters.com/article/brief-medtronic-begins-us-study-to-evalu/brief-medtronic-begins-u-s-study-to-evaluate-treatment-of-bifurcation-lesions-in-patients-with-coronary-artery-disease-idUSFWN1SN0T3,2018-05-16T14:02:05Z,BRIEF-Medtronic Begins U.S. Study To Evaluate Treatment Of Bifurcation Lesions In Patients With Coronary Artery Disease,May 16 (Reuters) - Medtronic PLC:,* MEDTRONIC BEGINS U.S. STUDY OF DRUG-ELUTING STENTS TO EVALUATE TREATMENT OF BIFURCATION LESIONS IN PATIENTS WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:
57,https://www.reuters.com/article/brief-mike-weinstein-to-join-medtronic-a/brief-mike-weinstein-to-join-medtronic-as-senior-vice-president-of-strategy-idUSASC0A008,2018-05-07T10:02:01Z,BRIEF-Mike Weinstein To Join Medtronic As Senior Vice President Of Strategy,May 7 (Reuters) - Medtronic PLC:,* MIKE WEINSTEIN TO JOIN MEDTRONIC AS SENIOR VICE PRESIDENT OF STRATEGY Source text for Eikon: Further company coverage:
58,https://www.reuters.com/article/brief-uks-cma-says-revoked-initial-enfor/brief-uks-cma-says-revoked-initial-enforcement-order-on-completed-acquisition-by-medtronic-of-animas-corp-assets-idUSFWN1S911F,2018-05-02T14:12:54Z,BRIEF-UK's CMA says Revoked Initial Enforcement Order On Completed Acquisition By Medtronic Of Animas Corp Assets,May 2 (Reuters) -,* UK'S CMA - HAS REVOKED INITIAL ENFORCEMENT ORDER MADE ON FEB 19 IN RELATION TO COMPLETED ACQUISITION BY MEDTRONIC PLC OF CERTAIN ASSETS OF ANIMAS CORP Source text (bit.ly/2jqGZ9X) Further company coverage:
59,https://www.reuters.com/article/brief-medtronic-announces-new-paid-famil/brief-medtronic-announces-new-paid-family-care-leave-benefits-idUSFWN1S8087,2018-05-01T13:06:21Z,BRIEF-Medtronic Announces New Paid Family Care Leave Benefits,May 1 (Reuters) - Medtronic PLC:,"* MEDTRONIC - EXPANDED PAID FAMILY LEAVE BENEFITS; ALL FULL-TIME, PART-TIME U.S. EMPLOYEES TO BE COVERED UNDER MEDTRONIC FAMILY CARE LEAVE POLICY Source text for Eikon: Further company coverage:"
60,https://www.reuters.com/article/brief-medtronic-receives-fda-approval-fo/brief-medtronic-receives-fda-approval-for-deep-brain-stimulation-therapy-for-type-of-epilepsy-idUSASC09YL4,2018-05-01T12:07:36Z,BRIEF-Medtronic Receives FDA Approval For Deep Brain Stimulation Therapy For Type Of Epilepsy,May 1 (Reuters) - Medtronic PLC:,* MEDTRONIC RECEIVES FDA APPROVAL FOR DEEP BRAIN STIMULATION THERAPY FOR MEDICALLY REFRACTORY EPILEPSY,* MEDTRONIC PLC - FDA APPROVAL IS BASED ON BOTH BLINDED PHASE AND 7-YEAR FOLLOW-UP DATA COLLECTED IN CO’S CLINICAL TRIAL CALLED SANTE Source text for Eikon: Further company coverage:
61,https://www.reuters.com/article/brief-medtronic-announces-fda-approval-o/brief-medtronic-announces-fda-approval-of-infuse-bone-graft-in-new-spine-surgery-indications-idUSASC09Y8S,2018-04-30T18:43:32Z,BRIEF-Medtronic Announces FDA Approval Of Infuse Bone Graft In New Spine Surgery Indications,April 30 (Reuters) - Medtronic PLC:,* MEDTRONIC ANNOUNCES FDA APPROVAL OF INFUSE(TM) BONE GRAFT IN NEW SPINE SURGERY INDICATIONS USING PEEK INTERBODY IMPLANTS Source text for Eikon: Further company coverage:
62,https://www.reuters.com/article/us-edwards-lifesci-results/edward-lifesciences-heart-valve-sales-in-europe-disappoint-shares-fall-idUSKBN1HV2QI,2018-04-24T22:48:23Z,"Edward Lifesciences' heart valve sales in Europe disappoint, shares fall","(Reuters) - Edwards Lifesciences Corp's EW.N first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc MDT.N.","The company’s shares fell as much as 8.1 percent in after-market trading as sales of its premium non-invasive device, used to replace diseased aortic valves without open-heart surgery, is its biggest growth driver.","“Procedure growth in Europe was double digits this quarter, while our growth was lower due to a year-over-year shift in share to our largest competitor,” Chief Executive Officer Michael A. Mussallem said on a call with analysts.",The increasingly competitive market for transcatheter valves is expected to expand from $3 billion currently to $5 billion in 2021 as more types of patients get treated with the valves.,The company's closest rival is Medtronic and analysts expect the entry of Boston Scientific's BSX.N valve into the market by late 2018 to further heat up the competition.,"Edwards Lifesciences said its global sales of the heart valves rose 2.3 percent to $551.5 million in the quarter. However, analysts were expecting a sales of $579.64 million, according to Thomson Reuters I/B/E/S.","The company’s net profit fell to $206.6 million, or 96 cents a share, in the quarter ended March 31, compared with a $230.2 million, or $1.06 per share, a year earlier.","Excluding items, the company earned $1.22 per share, beating the average analyst estimate of $1.11 per share. Net sales rose 1.3 percent to $894.8 million in the quarter.","However, the company’s forecast for current quarter adjusted profit of $1.05 to $1.15 per share missed estimates. Analysts were expecting a profit of $1.17 per share.",The company raised its full-year earnings per share forecast range to $4.50-$4.70 from $4.43-$4.63.,Shares of the company were trading lower at $123.58 after the bell.
63,https://www.reuters.com/article/brief-medtronic-inpact-admiral-drug-coat/brief-medtronic-in-pact-admiral-drug-coated-balloon-receives-fda-approval-idUSASC09WTT,2018-04-23T14:04:02Z,BRIEF-Medtronic In.Pact Admiral Drug Coated Balloon Receives FDA Approval,April 23 (Reuters) - Medtronic PLC:,* MEDTRONIC IN.PACT(TM) ADMIRAL(TM) DRUG COATED BALLOON RECEIVES FDA APPROVAL TO TREAT LONG SFA LESIONS,* MEDTRONIC PLC - APPROVAL WAS BASED ON CLINICAL DATA FROM COMPLEX LESION IMAGING COHORTS OF IN.PACT GLOBAL STUDY Source text for Eikon: Further company coverage:
64,https://www.reuters.com/article/brief-arca-biopharma-and-medtronic-exten/brief-arca-biopharma-and-medtronic-extend-gencaro-clinical-trial-collaboration-agreement-idUSASC09WSQ,2018-04-23T12:32:47Z,BRIEF-Arca Biopharma And Medtronic Extend Gencaro Clinical Trial Collaboration Agreement,April 23 (Reuters) - ARCA Biopharma Inc:,* ARCA BIOPHARMA AND MEDTRONIC EXTEND GENCARO CLINICAL TRIAL COLLABORATION AGREEMENT,"* ARCA BIOPHARMA -MEDTRONIC HAS EXTENDED U.S., CANADIAN AND EUROPEAN CLINICAL TRIAL COLLABORATION AGREEMENT WITH ARCA FOR ADDITIONAL YEAR TO APRIL 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)"
65,https://www.reuters.com/article/brief-medtronic-announces-us-launch-of-o/brief-medtronic-announces-u-s-launch-of-optisphere-embolization-spheres-idUSFWN1RU0ZT,2018-04-17T15:23:34Z,BRIEF-Medtronic Announces U.S. Launch Of Optisphere Embolization Spheres,April 17 (Reuters) - Medtronic PLC:,"* MEDTRONIC - ANNOUNCES U.S. LAUNCH OF OPTISPHERE EMBOLIZATION SPHERES, A RESORBABLE EMBOLIC PLATFORM DESIGNED FOR EMBOLIZATION OF HYPERVASCULAR TUMORS Source text for Eikon: Further company coverage:"
